cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Codiak Biosciences Inc
3 own
4 watching
Current Price
$0.81
$0.06
(7.52%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
29.7M
52-Week High
52-Week High
7.15
52-Week Low
52-Week Low
0.3
Average Volume
Average Volume
0.69M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization29.7M
icon52-Week High7.15
icon52-Week Low0.3
iconAverage Volume0.69M
iconDividend Yield--
iconP/E Ratio--
What does the Codiak Biosciences Inc do?
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Codiak Biosciences Inc make?
News & Events about Codiak Biosciences Inc.
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual ...
Globe Newswire
2 months ago
exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models;biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 Systemically administered exoASO-C/EBP demonstrated extra-...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (Codiak), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten public offering of ...
Globe Newswire
5 months ago
Enrollment continues in Phase 1 clinical trial of IV-administered exoASO-STAT6 in patients with advanced hepatocellular carcinoma Prioritizing vaccine program funded by CEPI and advancement of engEx-AAV for gene delivery Plans to initiate Phase 2 studies of exoSTING and exoIL-12 paused Codiak ...
PR Newswire
5 months ago
Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical? Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical? PR Newswire NEW YORK, Aug. 18, 2022 NEW...
Frequently Asked Questions
Frequently Asked Questions
What is Codiak Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Codiak Biosciences Inc shares?
plus_minus_icon
How can I buy Codiak Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Codiak Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Codiak Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Codiak Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Codiak Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Codiak Biosciences Inc?
plus_minus_icon
What percentage is Codiak Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Codiak Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.81
$0.06
(7.52%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00